Niraparib-Bevacizumab
4-2021-0076
Phase 2 small_molecule active
Quick answer
Niraparib-Bevacizumab for Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active